|Videos|April 15, 2021
Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs discusses the role of PARP inhibitors in first line maintenance therapy in advanced ovarian cancer.
Advertisement
Advertisement
Related to this article
The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5